Allogene Therapeutics vs Lyell Immunopharma
ALLO and LYEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLO and LYEL compare
Lyell Immunopharma is the larger company, worth 1.3 times as much as Allogene Therapeutics ($413M against $311M).
Lyell Immunopharma scores higher on the StockData Score (6 against 3 for Allogene Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLO | LYEL |
|---|---|---|
| Size and price | ||
| Market cap | $311M | $413M |
| Share price | $0.900 | $16.86 |
| Change, 1 year | −23.7% | −4.6% |
| Change, 5 years | −95.2% | −92.2% |
| Beta (5Y) | 1.62 | 1.43 |
| Employees | 152 | – |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 27544× |
| P/B | 0.8× (better) | 2.1× |
| FCF yield | −35.0% | −33.9% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −63.4% |
| Revenue growth, 5Y average | – | −65.9% |
| Profitability | ||
| Operating margin | – | −1783580% |
| Net margin | – | −1701070% |
| FCF margin | – | −933100% |
| Return on equity | −49.3% (better) | −97.8% |
| Return on invested capital | −718% (better) | −1683% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −142.5× | – |
| Current ratio | 7.79 (better) | 4.02 |
| Altman Z-score | −4.92 (better) | −8.42 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 90.5% | 48.9% |
| Held by insiders | 15.0% | 45.0% |
| Insider net buying, 12 months | −$668K | $74.4M (better) |
| Short interest, % of float | 17.5% | 10.5% |
Go deeper
- ALLO stock overview
- ALLO income statement
- ALLO valuation and score
- LYEL stock overview
- LYEL income statement
- LYEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.